Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries and also in other parts of the world. NAFLD encompasses a histological spectrum ranging from simple steatosis to steatohepatitis, advanced fibrosis and inflammatory changes. It frequently occurs with features of the metabolic syndrome including obesity, type 2 diabetes mellitus, dyslipidemia and hypertension. In fact, the metabolic syndrome is a strong predictor of NAFLD. Recently, Niemann-Pick C1-like 1 (NPC1L1) has been shown to play a pivotal role in cholesterol absorption. Unlike mouse NPC1L1 protein, predominantly expressed in the intestines, human and rat NPC1L1 is also abundantly expressed in the liver. Though the exact functions of hepatic NPC1L1 remain unknown, NPC1L1 may facilitate the hepatic accumulation of cholesterol. This raises a potential possibility that ezetimibe may improve fatty liver formation. In this review, potential role of lipid metabolism in NAFLD and its possible modulation through NPC1L1 blockade is discussed.
Keywords: NAFLD, NPC1L1, metabolic syndrome, insulin resistance, steatosis, steatohepa-titis, fibrosis, type 2 diabetes mellitus, dyslipidemia, hypertension, Niemann-Pick C1-like 1, adipogenic/lipogenic, alcoholic steatohepatitis (NASH), transcription factor PPAR, lipogenic factor SREBP, C/EBP, Ezetimibe, hepatocytes, tu-mor necrosis factor (TNF), lipopolysaccaride (LPS)-mediated steatosis, unfolded pro-tein response (UPR), splanchnic lipolysis, ZOF rats, Akt phosphorylation, gluconeogenic en-zymes (PEPCK and G6Pase), SREBP1c, ChREBP, FoxO1, CHOP, p38, methionine choline-deficient, TNF-alpha, SREBP2, HNF1
Current Vascular Pharmacology
Title: Novel Role of NPC1L1 in the Regulation of Hepatic Metabolism: Potential Contribution of Ezetimibe in NAFLD/NASH Treatment
Volume: 9 Issue: 1
Author(s): Masayuki Yoshida
Affiliation:
Keywords: NAFLD, NPC1L1, metabolic syndrome, insulin resistance, steatosis, steatohepa-titis, fibrosis, type 2 diabetes mellitus, dyslipidemia, hypertension, Niemann-Pick C1-like 1, adipogenic/lipogenic, alcoholic steatohepatitis (NASH), transcription factor PPAR, lipogenic factor SREBP, C/EBP, Ezetimibe, hepatocytes, tu-mor necrosis factor (TNF), lipopolysaccaride (LPS)-mediated steatosis, unfolded pro-tein response (UPR), splanchnic lipolysis, ZOF rats, Akt phosphorylation, gluconeogenic en-zymes (PEPCK and G6Pase), SREBP1c, ChREBP, FoxO1, CHOP, p38, methionine choline-deficient, TNF-alpha, SREBP2, HNF1
Abstract: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries and also in other parts of the world. NAFLD encompasses a histological spectrum ranging from simple steatosis to steatohepatitis, advanced fibrosis and inflammatory changes. It frequently occurs with features of the metabolic syndrome including obesity, type 2 diabetes mellitus, dyslipidemia and hypertension. In fact, the metabolic syndrome is a strong predictor of NAFLD. Recently, Niemann-Pick C1-like 1 (NPC1L1) has been shown to play a pivotal role in cholesterol absorption. Unlike mouse NPC1L1 protein, predominantly expressed in the intestines, human and rat NPC1L1 is also abundantly expressed in the liver. Though the exact functions of hepatic NPC1L1 remain unknown, NPC1L1 may facilitate the hepatic accumulation of cholesterol. This raises a potential possibility that ezetimibe may improve fatty liver formation. In this review, potential role of lipid metabolism in NAFLD and its possible modulation through NPC1L1 blockade is discussed.
Export Options
About this article
Cite this article as:
Yoshida Masayuki, Novel Role of NPC1L1 in the Regulation of Hepatic Metabolism: Potential Contribution of Ezetimibe in NAFLD/NASH Treatment, Current Vascular Pharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157016111793744715
DOI https://dx.doi.org/10.2174/157016111793744715 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Systematic Review of Overweight, Obesity, and Type 2 Diabetes Among Asian American Subgroups
Current Diabetes Reviews Anti-Proliferative Activity of Standardized Methanol Extract of Coscinium fenestratum and Its Major Constituent, Berberine, Against Nasopharyngeal Carcinoma Cells
The Natural Products Journal The Gatekeeping Function in Personalized Medicine Initiatives
Current Pharmacogenomics and Personalized Medicine Structure and Sequence Based Analysis of Alpha-Amylase Evolution
Protein & Peptide Letters Analysis of Ion and pH Effects on Iron Response Element (IRE) and mRNA-Iron Regulatory Protein (IRP1) Interactions
Current Chemical Biology An Improved Synthetic Method of Saxagliptin Intermediate 3-Hydroxy-1- acetyladamantane and Its Characterization
Letters in Organic Chemistry Global View on Alzheimer’s Disease and Diabetes Mellitus: Threats, Risks and Treatment Alzheimer’s Disease and Diabetes Mellitus
Current Alzheimer Research Role of Vascular Endothelial Growth Factor in Kidney Disease
Current Vascular Pharmacology Molecular Mechanisms of Glucocorticoids Action: From Basic Research to Clinical Implications
Current Immunology Reviews (Discontinued) Vitamin E and All-Cause Mortality: A Meta-Analysis
Current Aging Science The Development and Progression of Atherosclerosis: Evidence supporting a Role for Endoplasmic Reticulum (ER) Stress Signaling
Cardiovascular & Hematological Disorders-Drug Targets Association of Platelet Activation with Vascular Cognitive Impairment: Implications in Dementia Development?
Current Vascular Pharmacology Use of Diverse Chemometric and Validation Methods to Accurately Predict Human Urotensin-II Receptor Antagonist Activity
Current Computer-Aided Drug Design Treatment of Leishmaniasis: A Review and Assessment of Recent Research
Current Pharmaceutical Design Antidiabetic Drugs as Antihypertensives: New Data on the Horizon
Current Vascular Pharmacology Mitochondria in Chronic Liver Disease
Current Drug Targets Obesity and Arterial Compliance Alterations
Current Vascular Pharmacology Improvement in Hypertension Management with Pharmacological and Non- Pharmacological Approaches: Current Perspectives
Current Pharmaceutical Design Global Life-Long Health Benefits of Repression of Hypothalamic NPY System by Central Leptin Gene Therapy
Current Topics in Medicinal Chemistry Copeptin in Preeclampsia Development
Current Women`s Health Reviews